The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles

Exclusion Criteria

• •Self-reported use of illicit drugs (e.g., amphetamine, cannabis, cocaine, methamphetamine, MDMA, LSD, ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.
• •History of significant allergic reaction or significant hypersensitivity to cannabis or to any of the other ingredients in the study products.
• •Current concomitant medication use that may interact with the study drug including inhibitors and inducers of CYP2CP and CYP3A4 as well as highly-protein bound drugs and drugs with a narrow therapeutic index such as warfarin, cyclosporine, and amphotericin B.
• •History of or current evidence of a significant medical condition that, in the opinion of the investigator or medical staff, will impact the participant's safety or interfere with study outcomes.
• •Evidence of current psychiatric condition (based on MINI for DSM-5).
• •Been in treatment previously for cannabis use disorder.
• •Receiving of any drug as part of a research study within the past 30 days.
• •History of epilepsy or other serious medical condition.